hologic , inc .notes to consolidated financial statements ( continued ) ( in thousands , except per share data ) acquisition and the adjustments did not have a material impact on the company 2019s financial position or results of operation .there have no other material changes to the purchase price allocation as disclosed in the company 2019s form 10-k for the year ended september 30 , 2006 .as part of the purchase price allocation , all intangible assets that were a part of the acquisition were identified and valued .it was determined that only customer relationship , trade name , developed technology and know how and in-process research and development had separately identifiable values .customer relationship represents r2 2019s strong active customer base , dominant market position and strong partnership with several large companies .trade name represents the r2 product names that the company intends to continue to use .order backlog consists of customer orders for which revenue has not yet been recognized .developed technology and know how represents currently marketable purchased products that the company continues to resell as well as utilize to enhance and incorporate into the company 2019s existing products .the estimated $ 10200 of purchase price allocated to in-process research and development projects primarily related to r2 2019s digital cad products .the projects added direct digital algorithm capabilities as well as a new platform technology to analyze images and breast density measurement .the projects were substantially completed as planned in fiscal 2007 .the deferred income tax asset relates to the tax effect of acquired net operating loss carry forwards that the company believes are realizable partially offset by acquired identifiable intangible assets , and fair value adjustments to acquired inventory as such amounts are not deductible for tax purposes .acquisition of suros surgical systems , inc .on july 27 , 2006 , the company completed the acquisition of suros surgical systems , inc .( suros ) , pursuant to an agreement and plan of merger dated april 17 , 2006 .the results of operations for suros have been included in the company 2019s consolidated financial statements from the date of acquisition as part of its mammography/breast care business segment .suros , located in indianapolis , indiana , develops , manufactures and sells minimally invasive interventional breast biopsy technology and products for biopsy , tissue removal and biopsy site marking .the initial aggregate purchase price for suros of approximately $ 248100 ( subject to adjustment ) consisted of 2300 shares of hologic common stock valued at $ 106500 , cash paid of $ 139000 , and approximately $ 2600 for acquisition related fees and expenses .the company determined the fair value of the shares issued in connection with the acquisition in accordance with eitf issue no .99-12 , determination of the measurement date for the market price of acquirer securities issued in a purchase business combination .the components and allocation of the purchase price , consists of the following approximate amounts: .
[['net tangible assets acquired as of july 27 2006', '$ 11800'], ['in-process research and development', '4900'], ['developed technology and know how', '46000'], ['customer relationship', '17900'], ['trade name', '5800'], ['deferred income taxes', '-21300 ( 21300 )'], ['goodwill', '202000'], ['estimated purchase price', '$ 267100']]
the acquisition also provides for a two-year earn out .the earn-out is payable in two annual cash installments equal to the incremental revenue growth in suros 2019 business in the two years following the closing. .

Question: what is the fair value of hologic common stock used to acquire suros?
Answer: 46.3